Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NAPOLI-1: Onivyde in metastatic pancreatic cancer
NCT01494506Phase 3Completed
- Sponsor
- Merrimack Pharmaceuticals
- Start
- Nov 2011
- Primary completion
- Feb 2014
- Modality
- Small Molecules
- Countries
- 15
01
Overview
Phase 3, randomised, open-label trial of irinotecan liposome injection (3 arms), sponsored by Merrimack Pharmaceuticals. Primary endpoint: Overall Survival at 25 months. Started Nov 2011; status: completed.
02
Drugs
irinotecan liposome injection
Beyond the preview
Go deeper on NCT01494506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01494506.